Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Reduced by Eversept Partners LP

Eversept Partners LP lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 30.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,242,125 shares of the company's stock after selling 992,513 shares during the period. Teva Pharmaceutical Industries accounts for about 4.4% of Eversept Partners LP's investment portfolio, making the stock its 6th biggest holding. Eversept Partners LP owned approximately 0.20% of Teva Pharmaceutical Industries worth $49,416,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Stifel Financial Corp lifted its holdings in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after acquiring an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. grew its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after purchasing an additional 33,277 shares during the period. Pinnbrook Capital Management LP acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $4,966,000. Asset Management One Co. Ltd. increased its stake in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $3,340,000. Institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research analyst reports. Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.42 during midday trading on Thursday, reaching $14.71. 8,358,482 shares of the company were exchanged, compared to its average volume of 9,938,244. The firm's 50-day simple moving average is $15.26 and its 200-day simple moving average is $17.58. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market capitalization of $16.68 billion, a price-to-earnings ratio of -10.14, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.